Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Treatment strategies have not been well established for thrombotic microangiopathy associated with malignant hypertension.

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

USV Pvt. Ltd. has introduced OnArni, a fixed dose combination of Sacubitril and Valsartan, for the management of Heart ...

Implantable cardioverter-defibrillators were no better than amiodarone for survival in chronic Chagas cardiomyopathy, though ...

USV introduces OnArni, a cost-effective heart failure medication at ₹8 per tablet, improving adherence and health outcomes.

Our Bureau, Mumbai Tuesday, October 15, 2024, 12:45 Hrs [IST] USV Pvt. Ltd. has introduced OnArni, a fixed dose combination ...

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in ...

New Delhi: Reviewing the justification for the variability of the kinetic data of the bioequivalence (BE) study report of the fixed-dose combination (FDC) cardiovascular drug Sacubitril plus Valsartan ...

Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when ...

Researchers have established that sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is not superior to enalapril in the treatment of heart failure (HF) in children who have ...

Medically reviewed by Richard N. Fogoros, MDMedically reviewed by Richard N. Fogoros, MD Guideline-directed medical therapy (GDMT) for heart failure describes evidence-based therapies that ...